register

News & Trends - Pharmaceuticals

Aussie digital health company hits new milestone in AstraZeneca partnership

Health Industry Hub | April 26, 2024 |

Pharma News: Fewer than 50% of asthma patients adhere to their prescribed preventative medications. An Australian digital health company has received US Food and Drug Administration (FDA) approval for its device monitoring technology to enhance outcomes for patients with asthma and chronic obstructive pulmonary disease (COPD).

Adherium’s Hailie Smartinhaler is designed to be compatible with AstraZeneca’s Airsupra (albuterol/budesonide) and Breztri (budesonide/glycopyrrolate/formoterol fumarate) inhaler devices. Airsupra is a rescue medication for asthma patients and Breztri is a triple combination therapy for COPD patients.

AstraZeneca has successfully used the technology in clinical trials and has piloted its use in programs to support patients in the management of their respiratory conditions.  

The Bluetooth-enabled Hailie sensor attaches to the inhaler and is then paired with the Hailie app. The system is designed to help with treatment adherence by tracking medication use and reminding patients if a dose is missed. 

Patients are able to share adherence reports with clinicians by uploading the data to a secure cloud-based portal. This remote patient management platform allows healthcare providers to review the patient’s medication usage and make treatment decisions based on real-time data.

Adherium CEO, Paul Mastoridis, said “Our mission at Adherium has always been to revolutionise the way respiratory conditions are managed. By securing FDA clearance for our Smartinhaler with Airsupra and Breztri, we’re bringing that vision to life, offering patients and healthcare providers a powerful tool in the fight against chronic respiratory diseases.”

Allergist Dr Bill McCann commented on the launch, saying “The combination of the Hailie Smartinhaler with Airsupra and Breztri devices represents a leap forward in our ability to treat and manage asthma and COPD.

“This integration allows for a more nuanced understanding of patient needs and the ability to adjust treatments in real-time, which is invaluable in achieving optimal patient outcomes.”

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

New combination therapy improves survival rates for Aussies with advanced prostate cancer

New combination therapy improves survival rates for Aussies with advanced prostate cancer

Health Industry Hub | February 14, 2025 |

A world-first treatment approach has demonstrated significant advancements in the management of metastatic castration-resistant prostate cancer (mCRPC) compared to conventional […]

More


News & Trends - Pharmaceuticals

'Don't just learn what illness is, learn what it feels like,' Dr Ben Bravery

‘Don’t just learn what illness is, learn what it feels like,’ Dr Ben Bravery

Health Industry Hub | February 14, 2025 |

With the iconic Sydney Harbour as a backdrop, the Merck Healthcare team came together for a dynamic and engaging kick-off […]

More


News & Trends - MedTech & Diagnostics

GE HealthCare, Lumus Imaging and GenesisCare unite to bring advanced technology to patients

GE HealthCare, Lumus Imaging and GenesisCare unite to bring advanced technology to patients

Health Industry Hub | February 14, 2025 |

GE HealthCare and Lumus Imaging have joined forces to enhance medical care in Sydney’s Campbelltown region, unveiling a state-of-the-art imaging […]

More


News & Trends - MedTech & Diagnostics

World-First mobile CT for regional healthcare

World-First mobile CT for regional healthcare

Health Industry Hub | February 14, 2025 |

An Australian X-ray technology company developing a world-first full-body mobile CT following the award of an up to US$16.4m (A$25m) […]

More


This content is copyright protected. Please subscribe to gain access.